Sava Infond d.o.o. Makes New $4.40 Million Investment in Boston Scientific Co. (NYSE:BSX)

Sava Infond d.o.o. acquired a new stake in Boston Scientific Co. (NYSE:BSX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 49,310 shares of the medical equipment provider's stock, valued at approximately $4,404,000. Boston Scientific accounts for about 0.8% of Sava Infond d.o.o.'s holdings, making the stock its 28th biggest holding.

Other large investors have also added to or reduced their stakes in the company. Kingsview Wealth Management LLC raised its stake in shares of Boston Scientific by 5.0% during the third quarter. Kingsview Wealth Management LLC now owns 5,970 shares of the medical equipment provider's stock valued at $500,000 after acquiring an additional 282 shares during the last quarter. Truvestments Capital LLC bought a new position in Boston Scientific during the 3rd quarter worth $49,000. The Manufacturers Life Insurance Company lifted its holdings in Boston Scientific by 1.8% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 1,120,466 shares of the medical equipment provider's stock worth $93,895,000 after buying an additional 20,330 shares during the period. D.A. Davidson & CO. grew its position in shares of Boston Scientific by 3.2% in the 3rd quarter. D.A. Davidson & CO. now owns 10,945 shares of the medical equipment provider's stock valued at $917,000 after buying an additional 342 shares during the last quarter. Finally, Avestar Capital LLC raised its position in shares of Boston Scientific by 10.3% during the third quarter. Avestar Capital LLC now owns 12,397 shares of the medical equipment provider's stock worth $1,039,000 after acquiring an additional 1,158 shares during the last quarter. Institutional investors own 89.07% of the company's stock.

Remove Ads

Boston Scientific Stock Down 1.5 %

Shares of BSX traded down $1.51 on Friday, reaching $99.29. The company's stock had a trading volume of 7,402,670 shares, compared to its average volume of 6,051,507. Boston Scientific Co. has a twelve month low of $66.80 and a twelve month high of $107.17. The stock has a market capitalization of $146.86 billion, a PE ratio of 79.43, a PEG ratio of 2.79 and a beta of 0.77. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The firm has a fifty day moving average of $102.16 and a 200-day moving average of $93.04.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Equities analysts predict that Boston Scientific Co. will post 2.85 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the transaction, the executive vice president now directly owns 5,502 shares of the company's stock, valued at $560,103.60. This trade represents a 75.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the company's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $104.25, for a total transaction of $487,368.75. Following the completion of the sale, the executive vice president now directly owns 28,454 shares of the company's stock, valued at $2,966,329.50. The trade was a 14.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 137,302 shares of company stock valued at $14,319,269 in the last three months. 0.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Barclays upped their target price on Boston Scientific from $111.00 to $118.00 and gave the company an "overweight" rating in a report on Monday, February 10th. StockNews.com cut shares of Boston Scientific from a "buy" rating to a "hold" rating in a research report on Saturday, March 8th. TD Cowen boosted their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the company a "buy" rating in a report on Thursday, December 12th. Piper Sandler increased their price target on Boston Scientific from $95.00 to $115.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. Finally, Stifel Nicolaus boosted their price objective on Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. Two analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $108.91.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.